Clinical Trial Update: Dose-Defining Safety and Immunogenicity Study of MTBVAC in South African Neonates [Phase 2]

View source ↗

Summary

This update reports the completion of a Phase 2 dose-defining safety and immunogenicity trial of the TB vaccine MTBVAC in South African neonates.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tuberculosis

Drugs mentioned

• MTBVAC

Snippet

Sponsor: Biofabri, S.L | Conditions: Tuberculosis | Phase 2 | Status: COMPLETED